• 1. Fast synthesis of copper nanoclusters through the use of hydrogen peroxide additive and their application for the fluorescence detection of Hg2+ in water samples?
  Liao Xiaoqing,Li Ruiyi,Li Zaijun,Sun Xiulan,Wang Zhouping,Liu Junkang New J. Chem., 2015,39, 5240-5248
• 2. Fate of Sb(v) and Sb(iii) species along a gradient of pH and oxygen concentration in the Carnoulès mine waters (Southern France)
  Eléonore Resongles,Corinne Casiot,Fran?oise Elbaz-Poulichet,Rémi Freydier,Odile Bruneel,Christine Piot,Sophie Delpoux,Aurélie Volant,Angélique Desoeuvre Environ. Sci.: Processes Impacts, 2013,15, 1536-1544
• 3. Examination of deposit in commercial diluted phosphoric acid
  Analyst, 1880,5, 146-147
• 4. Evidence of CO2 molecule acting as an electron acceptor on a nanoporous metal–organic-framework MIL-53 or Cr3+(OH)(O2C–C6H4–CO2)?
  Alexandre Vimont,Arnaud Travert,Philippe Bazin,Jean-Claude Lavalley,Marco Daturi,Christian Serre,Gérard Férey,Sandrine Bourrelly,Philip L. Llewellyn Chem. Commun., 2007, 3291-3293
• 5. Distinct correlation between (CN2)x units and pores: a low-cost method for predesigned wide range control of micropore size of porous carbon?
  Xiaotong Feng,Lei Bian,Jie Ma,Lei Zhou,Xiayan Wang,Guangsheng Guo,Qiaosheng Pu Chem. Commun., 2019,55, 3963-3966

4-chloro-2,6-dimethyl-7H-pyrrolo[2,3-d]pyrimidine (CAS No. 1638764-22-3): A Versatile Intermediate in Modern Pharmaceutical Synthesis

4-chloro-2,6-dimethyl-7H-pyrrolo[2,3-d]pyrimidine, identified by its CAS number 1638764-22-3, is a significant intermediate in the realm of pharmaceutical chemistry. This heterocyclic compound, belonging to the pyrrolopyrimidine class, has garnered considerable attention due to its structural versatility and its role in the synthesis of various biologically active molecules.

The< strong>pyrrolo[2,3-d]pyrimidine scaffold is a privileged structure in medicinal chemistry, known for its ability to interact with biological targets such as enzymes and receptors. The introduction of chloro and methyl substituents at specific positions enhances its reactivity, making it a valuable building block for drug discovery programs. Specifically, the< strong>4-chloro substituent at the 4-position provides a site for further functionalization via nucleophilic aromatic substitution or cross-coupling reactions, while the< strong>2,6-dimethyl groups contribute to steric and electronic properties that can influence the compound's binding affinity and pharmacokinetic profile.

In recent years, there has been a surge in research focused on developing novel therapeutic agents targeting various diseases. Among these, cancers and infectious diseases have been prominent areas of interest. The< strong>4-chloro-2,6-dimethyl-7H-pyrrolo[2,3-d]pyrimidine core structure has been incorporated into several lead compounds that exhibit promising preclinical activity. For instance, derivatives of this compound have shown inhibitory effects on kinases and other enzymes involved in cancer cell proliferation and survival. These findings have spurred further investigation into optimizing the scaffold for improved efficacy and reduced toxicity.

The< strong>CAS no. 1638764-22-3 designation ensures that researchers can reliably obtain this compound for their studies. Its synthesis typically involves multi-step organic transformations starting from readily available precursors. Advanced synthetic methodologies, such as transition metal-catalyzed coupling reactions and microwave-assisted synthesis, have been employed to enhance yield and purity. These techniques not only streamline the production process but also allow for the rapid exploration of structural analogs.

The pharmaceutical industry has increasingly recognized the importance of heterocyclic compounds in drug development. The< strong>pyrrolopyrimidine moiety is particularly favored due to its presence in numerous FDA-approved drugs. The< strong>4-chloro-2,6-dimethyl-7H-pyrrolo[2,3-d]pyrimidine derivative exemplifies how modifications to a core scaffold can yield compounds with tailored biological activities. Researchers are continuously exploring new synthetic routes and functionalization strategies to expand the chemical space accessible from this intermediate.

The incorporation of computational chemistry techniques has further accelerated the discovery process. Molecular modeling studies have been instrumental in predicting binding modes and affinity interactions between< strong>4-chloro-2,6-dimethyl-7H-pyrrolo[2,3-d]pyrimidine-based compounds and their target proteins. These insights guide experimental design and help prioritize candidates for further development. Additionally, high-throughput screening (HTS) platforms have been utilized to rapidly assess the activity of large libraries of derivatives.

In conclusion, 4-chloro-2,6-dimethyl-7H-pyrrolo[2,3-d]pyrimidine (CAS No. 1638764-22-3) represents a crucial intermediate in modern pharmaceutical synthesis. Its structural features make it an excellent candidate for generating novel therapeutic agents with potential applications in oncology and other therapeutic areas. As research progresses, advancements in synthetic methodologies and computational tools will continue to drive innovation in this field.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)